Cost and clinical consequence of antibiotic non-adherence in acute exacerbations of chronic bronchitis

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 8, 2009, Pages 945-954

  Sorensen, S V ^a   Baker, T ^a   Fleurence, R ^a   Dixon, J ^a   Roberts, C ^b   Haider, S ^b   Hughes, Dyfrig ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b PFIZER INC   (United States)

^c BANGOR UNIVERSITY   (United Kingdom)

Author keywords

Acute exacerbations of chronic bronchitis; Adherence; Costs

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM; CEPHALOSPORIN; CEPHAMYCIN DERIVATIVE; MACROLIDE; METRONIDAZOLE; PENICILLIN DERIVATIVE; PENICILLIN G; PENICILLIN V; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM;

ACUTE OTITIS MEDIA; ANTIBIOTIC THERAPY; CHRONIC BRONCHITIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST MINIMIZATION ANALYSIS; DECISION SUPPORT SYSTEM; DISEASE EXACERBATION; DRUG TREATMENT FAILURE; ECONOMICS; HEALTH CARE COST; HEALTH SURVEY; HUMAN; INFLUENZA; ITALY; LARYNGITIS; MEDICAL LITERATURE; MODEL; PATIENT COMPLIANCE; PERTUSSIS; PHARYNGITIS; PHYSICIAN; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RHINOSINUSITIS; RISK FACTOR; SINUSITIS; SPAIN; SYSTEMATIC REVIEW; TONSILLITIS; TREATMENT OUTCOME; UNITED STATES;

ANTI-BACTERIAL AGENTS; BRONCHITIS; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; HUMANS; ITALY; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; SPAIN; UNITED STATES;

EID: 69249183216     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. McGuire A, Irwin D E, Fenn P, et al. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health 2001; 4: 370-375. (Pubitemid 32946235)
2. Halpern M T, Higashi M K, Bakst A W, Schmier J K. The economic impact of acute exacerbations of chronic bronchitis in the United States and Canada: a literature review. J Manag Care Pharm 2003; 9: 353-359.
3. Niederman M S, McCombs J S, Unger A N, Kumar A, Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 1999; 21: 576-591. (Pubitemid 29198043)
4. Ram F S, Rodriguez-Roisin R, Granados-Navarrette A, Garcia-Aymerich J, Barnes N C. Antibiotics for exacerbations of chronic obstructive pulmonary disease (Review). Cochrane Database Syst Rev 2006; 2: CD004403. (Pubitemid 46841358)
5. Anzueto A. Treatment of acute exacerbations of chronic bronchitis: antibiotic therapy. Semin Respir Crit Care Med 2000; 21: 97-106. (Pubitemid 30463942)
6. Kardas P, Devine S, Golembesky A, Roberts C. A systematic review and meta-analysis of misuse of antibiotic therapies in the community. Int J Antimicrob Agents 2005; 26: 106-113. (Pubitemid 41021961)
7. Pechere J C, Hughes D, Kardas P, Cornaglia G. Non-compliance with antibiotic therapy for acute community infections: a global survey. Int J Antimicrob Agents 2007; 29: 245-253. (Pubitemid 46240754)
8. Branthwaite A, Pechere J C. Pan-European survey of patients' attitudes to antibiotics and antibiotic use. J Int Med Res 1996; 24: 229-238. (Pubitemid 26168233)
9. Green J L, Ray S P, Charney E. Recurrence rate of streptococcal pharyngitis related to oral penicillin. J Pediatr 1969; 75: 292-294.
10. Jordan W C. The efficacy of doxycycline vs. tetracycline in treatment of gonorrhea in men. J Natl Med Assoc 1980; 72: 987-989. (Pubitemid 11255724)
11. Alger L S, Lovchik J C. Comparative efficacy of clindamycin versus erythromycin in eradication of antenatal Chlamydia trachomatis. Am J Obstet Gynecol 1991; 165: 375-381.
12. Anastasio G D, Little J M Jr, Robinson M D, Pettice Y L, Leitch B B, Norton H J. Impact of compliance and side effects on the clinical outcome of patients treated with oral erythromycin. Pharmacotherapy 1994; 14: 229-234.
13. Cheung R, Sullens C M, Seal D, et al. The paradox of using a 7-day antibacterial course to treat urinary tract infections in the community. Br J Clin Pharmacol 1988; 26: 391-398. (Pubitemid 18251664)
14. Venuta A, Laudizi L, Beverelli A, Bettelli F, Milioli S, Garetti E. Azithromycin compared with clarithromycin for the treatment of streptococcal pharyngitis in children. J Int Med Res 1998; 26: 152-158. (Pubitemid 28375299)
15. Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) Pneumonia Study Group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet 2002; 360: 835-841. (Pubitemid 35257947)
16. Agarwal G, Awasthi S, Kabra S K, Kaul A, Singhi S, Walter S D. Three-day versus five-day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. BMJ 2004; 328: 791.
17. Nicolau D. Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections. J Antimicrob Chemother 2002; 50 (Suppl 1): S61-S70. (Pubitemid 35049520)
18. Segador J, Gil-Guillen V F, Orozco D, et al. The effect of written information on adherence to antibiotic treatment in acute sore throat. Int J Antimicrob Agents 2005; 26: 56-61. (Pubitemid 40854117)
19. Claxton A J, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310. (Pubitemid 32804122)
20. Hughes D A, Bagust A, Haycox A, Walley T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001; 10: 601-615. (Pubitemid 32998372)
21. Urquhart J. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens. Pharmacoeconomics 1999; 15: 217-228. (Pubitemid 29133459)
22. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother 2002; 49: 897-903. (Pubitemid 34692883)
23. Halpern M T, Palmer C S, Zodet M, Kirsch J. Cost-effectiveness of gemifloxacin: results from the GLOBE study. Am J Health Syst Pharm 2002; 59: 1357-1365. (Pubitemid 34761540)
24. van Barlingen H H, Nuijten M J C, Volmer T, Sanderson D J, Lacey L F. Model to evaluate the cost-effectiveness of different antibiotics in the management of acute bacterial exacerbations of chronic bronchitis in Germany. J Med Econ 1998; 1: 201-218. (Pubitemid 29017518)
25. El Moussaoui R, Roede B M, Speelman P, Bresser P, Prins J M, Bossuyt P M. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 2008; 63: 415-422. (Pubitemid 351692349)
26. DiMatteo M. Variations in patient's adherence to medical recommendation: a quantitative review of 50 years of research. Med Care [Review] 2004; 42: 200-209.
27. Miravitlles M, Murio C, Guerrero T, Gisbert R. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449-1455. (Pubitemid 34499654)
28. Consejo General do Colegios Oficiales de Farmacéuticos. Base de datos del medicamento. Madrid, Spain: Consejo General do Colegios Oficiales de Farmacéuticos, 2006. www.portalfarma. com/home.nsf Accessed May 2007. [Spanish]
29. Destache C J, Dewan N, O'Donohue W J, Campbell J C, Angelillo V A. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 43 (Suppl A): S107-S113. (Pubitemid 29123509)
30. Ministerio de Defensa y la Generalitat Valenciana. Boletín Oficial del Estado 179 de 28/7/2006 (BOE). Valencia, Spain: Ministerio de Defensa, 2006. [Spanish]
31. 2006 Physicians fee and coding guide. Duluth, GA, USA: MAG Mutual Healthcare Solutions, 2006.
32. Agency for Healthcare Research and Quality. Health care cost and utilization project: nationwide in-patient sample (NIS). Rockville, MD, USA: AHRQ, 2004. www.ahrq.gov/data/hcup/ Accessed May 2009.
33. US Department of Health & Human Services, Centers for Medicare & Medicaid Services. Impact file for IPPS FY 2006 Final Rule. Washington DC, USA: US Department of Health & Human Services, 2005. www.cms.hhs.gov/ AcuteInpatientPPS/ FFD/list.asp?listpage=2 Accessed April 2007.
34. US Department of Labor, Bureau of Labor Statistics. Consumer price index. US Department of Labor, 2007. data.bls.gov/cgi-bin/ srgate Accessed April 2007.
35. Briggs A, Tambour M. The design and analysis of stochastic cost-effectiveness studies for the evaluation of health care interventions. Drug Information J 2001; 35: 1455-1468. (Pubitemid 34563438)
36. Henry D C, Riffer E, Sokol W N, Chaudry N I, Swanson R N. Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob Agents Chemother 2003; 47: 2770-2774. (Pubitemid 37040246)
37. Arguedas A, Emparanza P, Schwartz R H, et al. A randomized, multicenter, double-blind, double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media. Pediatr Infect Dis J 2005; 24: 153-161. (Pubitemid 40250775)
38. Arguedas A G, Zaleska M, Stutman H R, Blumer J L, Hains C S. Comparative trial of cefprozil vs. amoxicillin clavulanate potassium in the treatment of children with acute otitis media with effusion. Pediatr Infect Dis J 1991; 10: 375-380.
39. Block S L, Schmier J K, Notario G F, et al. Efficacy, tolerability and parent reported outcomes for cefdinir vs. high-dose amoxicillin/clavulanate oral suspension for acute otitis media in young children. Curr Med Res Opin 2006; 22: 1839-1847.
40. Block S L, Cifaldi M, Gu Y, Paris M M. A comparison of 5 days of therapy with cefdinir or azithromycin in children with acute otitis media: a multicenter, prospective, single-blind study. Clin Ther 2005; 27: 786-794. (Pubitemid 41583527)
41. Blumer J L, Bertino J S Jr, Husak M P. Comparison of cefaclor and trimethoprim-sulfamethoxazole in the treatment of acute otitis media. Pediatr Infect Dis 1984; 3: 25-29. (Pubitemid 14158840)
42. Feldman W, Sutcliffe T, Dulberg C. Twice-daily antibiotics in the treatment of acute otitis media: trimethoprim-sulfamethoxazole versus amoxicillin-clavulanate. CMAJ 1990; 142: 115-118. (Pubitemid 20039261)
43. Sunderland R, McVey D L. Cefixime versus co-amoxiclav in the treatment of pediatric upper respiratory tract infections and otitis media. A multicenter clinical study of empirical treatment in general practice in the United Kingdom. Curr Thera Res 1994; 55 (Suppl A): S22-S29.
44. Batieha A, Yahia G, Mahafzeh T, Omari M, Momani A, Dabbas M. No advantage of treating acute respiratory tract infections with azithromycin in a placebo-controlled study. Scand J Infect Dis 2002; 34: 243-247. (Pubitemid 34520665)
45. MacFarlane J T, Prewitt J, Gard P, Guion A. Comparison of amoxycillin and clarithromycin as initial treatment of community-acquired lower respiratory tract infections. Br J Gen Pract 1996; 46: 357-360. (Pubitemid 26197448)
46. Calver A D, Walsh N S, Quinn P F, et al. Dosing of amoxicillin/ clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Lower Respiratory Tract Infection Collaborative Study Group. Clin Infect Dis 1997; 24: 570-574.
47. Hosie J, Quinn P, Smits P, Sides G. A comparison of 5 days of dirithromycin and 7 days of clarithromycin in acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother 1995; 36: 173-183.
48. Martinot J B, Carr W D, Cullen S, et al. A comparative study of clarithromycin modified release and amoxicillin/clavulanic acid in the treatment of acute exacerbation of chronic bronchitis. Adv Ther 2001; 18: 1-11. (Pubitemid 32382433)
49. Nalepa P, Dobryniewska M, Busman T, Notario G. Short-course therapy of acute bacterial exacerbation of chronic bronchitis: a double-blind, randomized, multicenter comparison of extended-release versus immediate-release clarithromycin. Curr Med Res Opin 2003; 19: 411-420. (Pubitemid 36994444)
50. Vetter N, Argryopoulou-Pataka P. Efficacy and safety of once-daily and twice-daily clarithromycin formulations in the treatment of acute exacerbations of chronic bronchitis. Advances in Therapy 1999; 16: 13-21. (Pubitemid 29165106)
51. Lebel M H, Mehra S. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial. Pediatr Infect Dis J 2001; 20: 1149-1154. (Pubitemid 34016428)
52. Carbon C, Chatelin A, Bingen E, et al. A double-blind randomized trial comparing the efficacy and safety of a 5-day course of cefotiam hexetil with that of a 10-day course of penicillin V in adult patients with pharyngitis caused by group A beta-haemolytic streptococci. J Antimicrob Chemother 1995; 35: 843-854.
53. De Meyere M, Mervielde Y, Verschraegen G, Bogaert M. Effect of penicillin on the clinical course of streptococcal pharyngitis in general practice. Eur J Clin Pharmacol 1992; 43: 581-585.
54. Fyllingen G, Arnesen A R, Biermann C, et al. Phenoxymethyl-penicillin two or three times daily for tonsillitis with betahaemolytic streptococci group A: a blinded, randomized and controlled clinical study. Scand J Infect Dis 1991; 23: 553-558.
55. Gerber M A, Spadaccini L J, Wright L L, Deutsch L, Kaplan E L. Twice-daily penicillin in the treatment of streptococcal pharyngitis. Am J Dis Child 1985; 139: 1145-1148. (Pubitemid 16258043)
56. Schwartz R H, Wientzen R L Jr, Pedreira F, Feroli E J, Mella G W, Guandolo V L. Penicillin V for group A streptococcal pharyngotonsillitis. A randomized trial of seven vs ten days' therapy. JAMA 1981; 246: 1790-1795.
57. Urien A M, Guillen V F, Beltran D O, et al. Telephonic back-up improves antibiotic compliance in acute tonsillitis/pharyngitis. Int J Antimicrob Agents 2004; 23: 138-143.
58. Cook R C, Zachariah J, Cree F, Harrison H E. Efficacy of twice-daily amoxycillin/clavulanate ('Augmentin-Duo' 400/57) in mild to moderate lower respiratory tract infection in children. Br J Clin Pract 1996; 50: 125-128. (Pubitemid 26130611)
59. Pechere J C. Patients' interviews and misuse of antibiotics. Clin Infect Dis 2001; 33 (Suppl 3): S170-S173. [Spanish]
60. Haynes R B, McDonald H P, Garg A X. Helping patients follow prescribed treatment: clinical applications. JAMA 2002; 288: 2880-2883.